Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
about
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer TreatmentPrognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinomaThe role of immune checkpoint inhibition in the treatment of ovarian cancerEpithelial ovarian cancer - more data, more questions?Opportunities in immunotherapy of ovarian cancer.Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread.Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer.The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.The immune system and cancer evasion strategies: therapeutic concepts.Recently identified drug resistance biomarkers in ovarian cancer.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Tumor-derived exosomes induce CD8+ T cell suppressors.Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients.Role of intratumoral infiltrating macrophages after transarterial immunoembolization for hepatocellular carcinoma.Immune system and melanoma biology: a balance between immunosurveillance and immune escape.Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal.
P2860
Q26769963-FA3D5C50-E8EA-4C19-80EF-94B8CA08F867Q27853285-0EB1166F-BAD4-4E0A-8617-03D05BD225BFQ28077924-375A415B-3536-45AD-9912-BF5018DDA712Q30869183-68954A42-7118-459C-84B1-4E6CB3E92094Q36855245-E26C62BE-5B60-4873-A6A5-FE6811DCA34AQ37457617-2C6519EC-A386-4541-8B8A-950812143A8FQ37559965-C2A42199-7D03-4C8A-A468-86384DD528D1Q37716589-ABDABE54-09DD-42B6-8F18-1BC98A7A9776Q38202161-4DBE31F1-1C71-43E1-8BBA-EFD422622991Q38691172-2BF9924D-92A8-4057-A6CF-357BDED79482Q38741073-5DDD2CED-9365-40F5-92EC-DA56C4440371Q38770458-CED64495-6DFF-4958-B400-8DB87D71692AQ41392250-765ADE28-8E88-42AF-9A36-3AEB9ED570F3Q42056165-3CDBA1E4-C106-463F-96D5-616FB84154EEQ47111746-39148616-8A42-45C0-8B48-51CE2BCCDAC0Q47865300-C50795FF-A9C2-43E3-9006-F6947AAC5E92Q49166036-74DBA36C-DE4E-42F1-A0E4-76DAF34E3897Q53595435-ACEFC6D4-8480-42D1-9D57-9FED573731BB
P2860
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prognostic impact of tumor inf ...... study of the OVCAD consortium
@en
Prognostic impact of tumor inf ...... study of the OVCAD consortium.
@nl
type
label
Prognostic impact of tumor inf ...... study of the OVCAD consortium
@en
Prognostic impact of tumor inf ...... study of the OVCAD consortium.
@nl
prefLabel
Prognostic impact of tumor inf ...... study of the OVCAD consortium
@en
Prognostic impact of tumor inf ...... study of the OVCAD consortium.
@nl
P2093
P2860
P50
P356
P1433
P1476
Prognostic impact of tumor inf ...... study of the OVCAD consortium
@en
P2093
Christoph Grimm
Eva Schuster
Georg Heinze
Reinhard Horvat
Stefanie Aust
Stephan Polterauer
Sven Mahner
Theresia Thalhammer
P2860
P2888
P356
10.1186/1471-2407-13-422
P407
P50
P577
2013-09-17T00:00:00Z
P5875
P6179
1030811046